Program
pirtobrutinib
Also written as “Pirtobrutinib”, “LOXO-305” and “[14C]-LOXO-305”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, B-Cell · Purpura, Thrombocytopenic, Idiopathic · Lymphoma, Mantle-Cell · Renal Insufficiency, led by 3 companies.
Drug pagePirtobrutinib: every studyAll 66 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 2811 open or running | phase 4since Mar 6, 2025 | Nov 6, 2018 | Oct 2027phase 3 · NCT05254743 |
| AstraZenecaits history only | 10 open or running | phase 2since Jan 21, 2025 | Jan 21, 2025 | none ahead |
| Nurix Therapeuticsits history only | 11 open or running | phase 3since Mar 31, 2026 | Mar 31, 2026 | Oct 2029phase 3 · NCT07516093 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Nov 6, 2018.
- Jul 15, 2021Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT04965493 · 600 enrolled · United States, Australia, Belgium and more
- Jul 28, 2021Named pirtobrutinibINNProposed as its International Nonproprietary Name in WHO's List 125 · before, LOXO-305
- Aug 24, 2021Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05023980 · 282 enrolled · United States, Australia, Austria and more
- Oct 22, 20212 phase 1 studies in Healthy VolunteersNCT05134350, NCT05134337
- Jan 3, 2022Phase 1 study in HealthyNCT05176314 · 32 enrolled · United States
- Feb 15, 2022Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05254743 · 737 planned · United States, Argentina, Australia and more
- Oct 24, 2023Phase 2 study in Multiple SclerosisNCT06104683 · United States, Puerto Rico
- Nov 30, 2023Phase 1 study in HealthyNCT06165146 · 16 enrolled · United States
- Dec 11, 20239 phase 1 studiesNCT06190691, NCT06190678, NCT06194214 and 6 more
- Feb 6, 2024Phase 1 study in HealthyNCT06258174 · 28 enrolled · United States
- Sep 6, 2024Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06588478 · 249 planned · United States, Australia, Belgium and more
- Dec 3, 2024Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT06721013 · 68 planned · United States, China, Denmark and more
- Mar 6, 20252 phase 4 studies in Leukemia, Lymphocytic, Chronic, B-CellNCT06876662, NCT06876649
- Aug 29, 2025Phase 2 study in Lymphoma, Non-HodgkinNCT07162181 · 13 enrolled · China
- Oct 16, 2025Phase 4 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07218341 · 150 planned · United States, Australia, Austria and more
Ahead
- Oct 2027Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05254743
- Nov 2027Primary completion: phase 3 study in Lymphoma, Mantle-CellNCT04662255
- Feb 2028Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT06721013
- Jun 2028Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06588478
TargetBeta
“An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 28 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07218341Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 4 | Recruiting | May 2030 | 150 |
| NCT07162181Lymphoma, Non-Hodgkin · China | 2 | Active, not recruiting | May 2030 | 13 |
| NCT06876662Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 4 | Recruiting | May 2030 | 279 |
| NCT06876649Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 4 | Recruiting | May 2030 | 787 |
| NCT06721013Purpura, Thrombocytopenic, Idiopathic · United States, China, Denmark and more | 2 | Recruiting | Feb 2028 | 68 |
| NCT06588478Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 2 | Recruiting | Jun 2028 | 249 |
| NCT06258174Healthy · United States | 1 | Completed | Dec 22, 2021 | 28 |
| NCT06215521Healthy · United States | 1 | Completed | Mar 31, 2021 | 31 |
| NCT06215430Healthy · United States | 1 | Completed | Apr 15, 2021 | 16 |
| NCT06194214Healthy · United States | 1 | Completed | Jun 9, 2021 | 16 |
| NCT06181006Healthy · United States | 1 | Completed | Dec 1, 2020 | 24 |
| NCT06180980Healthy · United States | 1 | Completed | Mar 8, 2021 | 20 |
| NCT06180967Healthy · United States | 1 | Completed | Oct 20, 2020 | 15 |
| NCT06180954Healthy · United States | 1 | Completed | Nov 6, 2020 | 9 |
| NCT06190691Hepatic Insufficiency · United States | 1 | Completed | Dec 30, 2021 | 36 |
| NCT06190678Renal Insufficiency · United States | 1 | Completed | Jun 4, 2021 | 16 |
| NCT06165146Healthy · United States | 1 | Completed | Dec 30, 2020 | 16 |
| NCT06104683Multiple Sclerosis · United States, Puerto Rico | 2 | Withdrawn | Jan 16, 2026 | 0 |
| NCT05254743Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more | 3 | Recruiting | Oct 2027 | 737 |
| NCT05176314Healthy · United States | 1 | Completed | Apr 20, 2022 | 32 |
| NCT05134350Healthy Volunteers · United States | 1 | Completed | Mar 23, 2020 | 10 |
| NCT05134337Healthy Volunteers · United States | 1 | Completed | Oct 30, 2020 | 27 |
| NCT05023980Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Jul 11, 2025 | 282 |
| NCT04965493Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Active, not recruiting | Oct 2026 | 600 |
| NCT04849416Leukemia, Lymphoid · China | 2 | Completed | Apr 10, 2023 | 87 |
| NCT04666038Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Aug 29, 2023 | 238 |
| NCT04662255Lymphoma, Mantle-Cell · United States, Australia, Austria and more | 3 | Active, not recruiting | Nov 2027 | 500 |
| NCT03740529Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, France and more | 2 | Completed | Jan 27, 2025 | 803 |
How it is read
Names in the registry
- “Pirtobrutinib”, 26 entries
- “LOXO-305”, 3 entries
- “[14C]-LOXO-305”, 2 entries
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 11 studies
- Lymphoma, B-Cell, 2 studies
- Purpura, Thrombocytopenic, Idiopathic, 1 study
- Lymphoma, Mantle-Cell, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.